Sanofi, Alnylam Q3 Reports Hint at Early Pipeline Impacts from IRA

The implications of the Inflation Reduction Act of 2022 (IRA), which is aimed at lowering the price of prescription drugs, are already reverberating across biopharma pipelines as companies hint at – or explicitly state – their impacts.